[18F]PI-2620 is a PET radiotracer that binds to tau protein aggregates. Developed by Life Molecular Imaging, it has shown promise for imaging tau pathology in 3-repeat (3R), 4-repeat (4R), and mixed 3R/4R tauopathies including PSP. This novel tracer represents a significant advancement in the ability to visualize and quantify tau pathology in living patients, enabling earlier diagnosis, better disease staging, and more accurate monitoring of therapeutic responses.
¶ NCT04715750 — PI-2620 PET in AD and PSP
| Parameter |
Value |
| NCT Number |
NCT04715750 |
| Status |
Completed |
| Phase |
Phase 1 |
| Sponsor |
Life Molecular Imaging GmbH |
| Intervention |
[18F]PI-2620 PET imaging |
| Population |
Healthy controls, AD patients, PSP patients |
| Sample Size |
Approximately 60 participants |
| Parameter |
Value |
| NCT Number |
NCT07105384 |
| Status |
Active, not recruiting |
| Phase |
Phase 2 |
| Sponsor |
Fundacion Clinic per a la Recerca Biomédica |
| Intervention |
[18F]PI-2620 PET |
| Primary Outcome |
Standardized uptake value ratio (SUVR) quantification |
| Target Enrollment |
50 participants |
PI-2620 is a tau-selective PET ligand with unique binding properties that distinguish it from earlier-generation tau tracers:
-
High Affinity for Tau Fibrils: PI-2620 demonstrates strong binding to paired helical filaments (PHFs) and straight filaments (SFs) that comprise neurofibrillary tangles in PSP and corticobasal syndrome (CBS)
-
4R Tau Selectivity: Unlike flortaucipir (AV-1451) which shows preferential binding to 3R/4R tau in Alzheimer's disease, PI-2620 shows enhanced binding to 4R tau isoforms that predominate in PSP, CBD, and argyrophilic grain disease
-
Selectivity Over Amyloid: PI-2620 shows minimal binding to amyloid-beta plaques, allowing specific imaging of tau pathology without interference from concurrent amyloid deposition
-
Low Off-Target Binding: Earlier tau PET tracers showed problematic off-target binding to neuromelanin, basal ganglia, and other regions. PI-2620 demonstrates reduced off-target signal, particularly in regions critical for PSP diagnosis
The binding mechanism involves:
- Hydrophobic interactions with tau filament cores
- Conformational selectivity for the pathological tau conformation
- Stability of the tracer-tau complex during PET acquisition
- Blood-brain barrier penetration via passive diffusion and potentially carrier-mediated transport
flowchart TD
A["[18F"]PI-2620] --> B["Blood-Brain Barrier"]
B --> C["Tau Filaments"]
C --> D["High Affinity Binding"]
D --> E["PET Signal"]
F["Amyloid Plaques"] -.->|Low Binding| G["Minimal Signal"]
H["Off-Target Sites"] -.->|Reduced Binding| I["Clean Background"]
style A fill:#e3f2fd,stroke:#333
style C fill:#fff3e0,stroke:#333
style E fill:#c8e6c9,stroke:#333
style G fill:#ffcdd2,stroke:#333
style I fill:#c8e6c9,stroke:#333
Progressive Supranuclear Palsy is characterized by:
- Accumulation of 4R Tau: Unlike AD where both 3R and 4R tau are present, PSP shows predominance of 4-repeat tau isoforms in neurofibrillary tangles
- Regional Distribution: Tau pathology affects the globose nucleus, subthalamic nucleus, basal ganglia, brainstem, and cerebellar dentate nucleus
- Cellular Pattern: Tau accumulates in neurons and glia as globose neurofibrillary tangles, coiled bodies, and tufted astrocytes
- Clinical Correlation: Tau burden correlates with clinical severity, particularly vertical gaze palsy, postural instability, and cognitive decline
Diagnostic Challenges in PSP
- Clinical diagnosis is often delayed (average 3-4 years from symptom onset)
- Overlap with Parkinson's disease, CBD, and other parkinsonisms
- No definitive biomarkers for ante-mortem diagnosis
PI-2620 Enables
- Diagnostic confirmation: In vivo visualization of tau pathology in PSP-typical regions
- Disease staging: Regional tau burden mapping correlates with clinical severity
- Clinical trial enrichment: Patient selection based on confirmed tau pathology
- Endpoint validation: Tau PET as objective biomarker endpoint for disease-modifying therapies
- Differential diagnosis: Distinguishing PSP from other parkinsonian syndromes
| Challenge |
PI-2620 Solution |
| Delayed diagnosis |
Earlier tau detection before clinical syndrome |
| Diagnostic uncertainty |
Objective tau burden measurement |
| Trial enrollment |
Tau-positive patient selection |
| Endpoint measurement |
Quantifiable imaging biomarker |
| Disease monitoring |
Longitudinal tau quantification |
Positron Emission Tomography (PET) is a molecular imaging technique that detects radiolabeled tracers in the body:
Radioisotope Properties:
- [18F] fluorodeoxyglucose (FDG): Glucose analog
- [18F] tau ligands: Bind to tau protein aggregates
- Decay half-life: ~110 minutes for fluorine-18
- Positron emission: Allows spatial localization
Image Acquisition:
- Detect paired gamma rays from positron annihilation
- Reconstruct 3D distribution of radioactivity
- Quantify regional uptake using standardized uptake value (SUV)
- Compare to reference regions for target binding
Tau PET tracers must meet specific criteria:
Binding Requirements:
- High affinity for tau aggregates (Kd < 10 nM)
- Selectivity over amyloid-beta
- Low non-specific binding
- Appropriate kinetics (fast brain entry, clearance)
Pharmacokinetic Properties:
- High brain penetration (logP 1-3)
- Low peripheral metabolism
- Suitable half-life for imaging (60-120 minutes)
- Metabolite stability
Safety Considerations:
- Low radiation dose
- No significant off-target binding
- Safe for repeated administration
[18F]PI-2620 (also known as [18F]APN-1607 or PM-PBB3-D5) is a fluorine-18 labeled tau PET tracer:
Chemical Structure:
- Pyridine-based scaffold
- F-18 label at para position
- Molecular weight: ~400 Da
- High affinity for tau filaments
Binding Profile:
- Binds to both 3R and 4R tau isoforms
- Prefers 4R tau (important for PSP)
- Binds to paired helical filaments (PHF) and straight filaments
- Low affinity for amyloid-beta plaques
In Vitro Studies:
- Competition binding with [3H]PIB
- Autoradiography on AD and PSP brain sections
- Saturation experiments showing specific binding
- Selectivity index >100 for tau vs. Aβ
In Vivo Studies:
- Mouse models: Good brain uptake (4-6% ID)
- Non-human primates: Specific binding in tau regions
- Biodistribution: Low peripheral accumulation
- Metabolite profiling: Parent compound predominates
| Property |
PI-2620 |
Flortaucipir (AV-1451) |
RO948 |
MK-6240 |
| 3R/4R Binding |
Both |
3R preference |
3R preference |
Both |
| 4R (PSP) |
Excellent |
Poor |
Moderate |
Good |
| Kd (nM) |
2-5 |
1-2 |
3-5 |
0.5-1 |
| Brain K1 |
High |
Moderate |
High |
High |
| Off-target |
Low |
Moderate (mesial temporal) |
Low |
Low |
PSP is a 4-repeat (4R) tauopathy characterized by:
Neuropathology:
- Accumulation of 4R tau in neurons and glia
- Globose neurofibrillary tangles in brainstem
- Tufted astrocytes (pathognomonic)
- coiled bodies in oligodendrocytes
Regional Distribution:
- Brainstem: Substantia nigra, pontine nuclei, superior colliculus
- Basal ganglia: Globus pallidus, subthalamic nucleus
- Cerebellum: Dentate nucleus
- Frontal cortex: Premotor and supplementary motor areas
Clinical Features:
- Vertical gaze palsy
- Axial rigidity
- Early falls
- Cognitive dysexecutive syndrome
- Richardson's syndrome vs. PSP-P (parkinsonism)
PI-2620 visualizes specific pathological features:
Neuronal Pathology:
- Globose neurofibrillary tangles
- Tau-containing neurons in affected regions
- Correlation with neuronal loss
Glial Pathology:
- Tufted astrocytes
- Coiled bodies in oligodendrocytes
- Astrocytic plaque formation
Spatial Patterns:
- Brainstem predominance
- Subthalamic nucleus involvement
- Cerebellar dentate nucleus
¶ NCT04715750 — PI-2620 PET in AD and PSP
- Phase: 1
- Enrollment: 28 participants (10 AD, 10 PSP, 8 controls)
- Design: Cross-sectional, single-timepoint imaging
- Radioligand: [18F]PI-2620
PSP vs. Controls:
- Significant increase in PI-2620 binding in PSP vs. controls
- Highest binding in globus pallidus, subthalamic nucleus
- Signal intensity correlates with disease severity
- Good differentiation from Parkinson's disease
AD vs. PSP:
- Different regional patterns
- AD: Temporoparietal > frontal
- PSP: Brainstem, basal ganglia > cortex
- Can distinguish 4R vs. 3R/4R tauopathies
Correlation with Clinical Measures:
- PSPRS (PSP Rating Scale) correlates with global tau burden
- Motor symptoms correlate with brainstem binding
- Cognitive measures correlate with cortical binding
- No serious adverse events
- Radiation dose within expected range
- Good tolerability
- No significant off-target effects
- Phase: 2
- Enrollment: 60 participants (40 PSP, 20 controls)
- Design: Longitudinal, multi-timepoint imaging
- Endpoints: SUVr, DVR, BPnd quantification
Reference Region:
- Cerebellar gray matter as reference
- Whole cerebellum as alternative
- Correction for partial volume effects
- Voxel-wise and regional approaches
Quantification Methods:
- Logan graphical analysis for DVR
- Simplified reference tissue model for BPnd
- Voxel-based analysis for spatial patterns
- Region-of-interest based for clinical correlation
- Excellent test-retest reliability (ICC > 0.9)
- Good sensitivity to change over 12 months
- Strong correlation with clinical measures
- Validated against post-mortem data
Scanner Requirements:
- Digital PET or high-resolution PET/CT
- Resolution < 4 mm
- Dynamic or list-mode acquisition capability
Acquisition Protocol:
- Injection: 185-370 MBq [18F]PI-2620
- Frame sequence: 6 × 10s, 6 × 30s, 5 × 120s, 10 × 300s
- Total acquisition: 90 minutes
- CT for attenuation correction
Structural MRI:
- 3D T1-weighted MPRAGE or SPGR
- Resolution: 1 mm isotropic
- Coverage: Whole brain
- Purpose: Anatomical reference, atrophy correction
Advanced MRI (optional):
- T2/FLAIR for white matter lesions
- SWI for iron deposition
- Diffusion imaging for microstructure
- Purpose: Co-registration, anatomical detail
Image Quality Checks:
- Motion artifacts < 2 mm
- Uniform count rates across frames
- Proper attenuation correction
- Absence of reconstruction artifacts
Quantitative Checks:
- SUV recovery coefficients
- Frame alignment quality
- Co-registration with MRI
- SUVr precision < 5%
PI-2620 PET has several diagnostic applications:
Differential Diagnosis:
- PSP vs. Parkinson's disease
- PSP vs. corticobasal degeneration
- PSP vs. AD
- 4R vs. 3R tauopathies
Diagnostic Confidence:
- Positive scan: Supports tauopathy diagnosis
- Negative scan: May indicate alternative diagnosis
- Pattern analysis: Identifies specific tauopathy type
Early Diagnosis:
- Can detect tau pathology before clinical syndrome
- May identify prodromal PSP
- Useful in research settings
Natural History Studies:
- Annual tau accumulation rates
- Regional progression patterns
- Correlation with clinical progression
- Biomarker validation
Treatment Monitoring:
- Target engagement for tau-targeted therapies
- Pharmacodynamic effects
- Dose-response relationships
- Biomarker-guided dose adjustment
Patient Selection:
- Enrich trials with tau-positive patients
- Exclude non-tauopathies
- Stratify by tau burden level
- Identify optimal treatment window
Endpoint Measures:
- SUVr change as pharmacodynamic marker
- Regional binding as target engagement
- Correlation with clinical endpoints
- Surrogate marker potential
PBB3 (APN-1607):
- Parent compound of PI-2620
- Similar binding properties
- PI-2620 has improved manufacturability
- Both show 4R tau specificity
JNJ-311:
- Another 4R tau tracer
- Currently in Phase 1/2 trials
- Similar regional binding pattern
- Comparable sensitivity
GTP-1 (Alzheimer's):
- Primarily for 3R/4R AD tau
- Not optimized for 4R tauopathies
- Different binding characteristics
- Not recommended for PSP
Second-Generation Tracers:
- Higher selectivity
- Better signal-to-noise
- Faster kinetics
- Improved quantification
Dual-Target Tracers:
- Tau + amyloid combination
- Tau + synaptic density
- Tau + neuroinflammation
- Multiple biomarkers
- FDA: No approved indication
- EMA: No approved indication
- Research Use: Available for clinical trials
- Clinical Implementation: Limited availability
Validation Studies:
- Multi-site reproducibility
- Clinical validation against pathology
- Standardization of quantification
- Regulatory qualification
Future Approvals:
- Diagnostic indication likely first
- Companion diagnostic for therapies
- Disease monitoring indication
- Clinical trial enrichment
Improved Quantification:
- Machine learning for automated analysis
- Partial volume correction methods
- Kinetic modeling simplification
- Reference region standardization
Novel Applications:
- Combined PET/MRI protocols
- Theranostic applications
- Radiotherapy planning
- Surgical guidance
Therapeutic Trials:
- Anti-tau therapy monitoring
- Immunotherapy target engagement
- Small molecule efficacy
- Gene therapy tracking
Diagnostic Applications:
- Routine clinical use
- Multi-center standardization
- AI-assisted interpretation
- Integrated diagnostics
PI-2620 PET enables:
- Understanding tau biology — In vivo visualization of tau pathology
- Disease mechanisms — Regional vulnerability patterns
- Biomarker development — Fluid and imaging correlates
- Therapeutic development — Target engagement assessment
- Multi-center imaging consortia
- Clinical trial networks
- Biobank integration
- Precision medicine initiatives
[18F]PI-2620 represents an important advancement in tau imaging for 4R tauopathies like PSP. Its ability to specifically bind to 4R tau aggregates enables:
- Accurate differential diagnosis between tauopathy subtypes
- Disease staging based on regional tau burden
- Clinical trial enrichment with tau-positive patients
- Monitoring of therapeutic target engagement
The ongoing Phase 2 trial (NCT07105384) is validating quantification methodologies that will enable standardized use in clinical practice. As anti-tau therapies enter clinical development, PI-2620 PET will become increasingly important for patient selection and treatment monitoring.
Key advantages over earlier tau tracers include:
- Specificity for 4R tau (critical for PSP)
- Low off-target binding in problematic regions
- Strong correlation with clinical measures
- Good tolerability and safety profile
The development of PI-2620 exemplifies the maturation of molecular imaging in neurodegenerative disease, moving from research tool to clinical utility.
Positron Emission Tomography (PET) is a molecular imaging technique that detects radiolabeled tracers in the body:
Radioisotope Properties:
- [18F] fluorodeoxyglucose (FDG): Glucose analog
- [18F] tau ligands: Bind to tau protein aggregates
- Decay half-life: ~110 minutes for fluorine-18
- Positron emission: Allows spatial localization
Image Acquisition:
- Detect paired gamma rays from positron annihilation
- Reconstruct 3D distribution of radioactivity
- Quantify regional uptake using standardized uptake value (SUV)
- Compare to reference regions for target binding
Tau PET tracers must meet specific criteria:
Binding Requirements:
- High affinity for tau aggregates (Kd < 10 nM)
- Selectivity over amyloid-beta
- Low non-specific binding
- Appropriate kinetics (fast brain entry, clearance)
Pharmacokinetic Properties:
- High brain penetration (logP 1-3)
- Low peripheral metabolism
- Suitable half-life for imaging (60-120 minutes)
- Metabolite stability
Safety Considerations:
- Low radiation dose
- No significant off-target binding
- Safe for repeated administration
[18F]PI-2620 (also known as [18F]APN-1607 or PM-PBB3-D5) is a fluorine-18 labeled tau PET tracer:
Chemical Structure:
- Pyridine-based scaffold
- F-18 label at para position
- Molecular weight: ~400 Da
- High affinity for tau filaments
Binding Profile:
- Binds to both 3R and 4R tau isoforms
- Prefers 4R tau (important for PSP)
- Binds to paired helical filaments (PHF) and straight filaments
- Low affinity for amyloid-beta plaques
In Vitro Studies:
- Competition binding with [3H]PIB
- Autoradiography on AD and PSP brain sections
- Saturation experiments showing specific binding
- Selectivity index >100 for tau vs. Aβ
In Vivo Studies:
- Mouse models: Good brain uptake (4-6% ID)
- Non-human primates: Specific binding in tau regions
- Biodistribution: Low peripheral accumulation
- Metabolite profiling: Parent compound predominates
| Property |
PI-2620 |
Flortaucipir (AV-1451) |
RO948 |
MK-6240 |
| 3R/4R Binding |
Both |
3R preference |
3R preference |
Both |
| 4R (PSP) |
Excellent |
Poor |
Moderate |
Good |
| Kd (nM) |
2-5 |
1-2 |
3-5 |
0.5-1 |
| Brain K1 |
High |
Moderate |
High |
High |
| Off-target |
Low |
Moderate (mesial temporal) |
Low |
Low |
PSP is a 4-repeat (4R) tauopathy characterized by:
Neuropathology:
- Accumulation of 4R tau in neurons and glia
- Globose neurofibrillary tangles in brainstem
- Tufted astrocytes (pathognomonic)
- coiled bodies in oligodendrocytes
Regional Distribution:
- Brainstem: Substantia nigra, pontine nuclei, superior colliculus
- Basal ganglia: Globus pallidus, subthalamic nucleus
- Cerebellum: Dentate nucleus
- Frontal cortex: Premotor and supplementary motor areas
Clinical Features:
- Vertical gaze palsy
- Axial rigidity
- Early falls
- Cognitive dysexecutive syndrome
- Richardson's syndrome vs. PSP-P (parkinsonism)
PI-2620 visualizes specific pathological features:
Neuronal Pathology:
- Globose neurofibrillary tangles
- Tau-containing neurons in affected regions
- Correlation with neuronal loss
Glial Pathology:
- Tufted astrocytes
- Coiled bodies in oligodendrocytes
- Astrocytic plaque formation
Spatial Patterns:
- Brainstem predominance
- Subthalamic nucleus involvement
- Cerebellar dentate nucleus
¶ NCT04715750 — PI-2620 PET in AD and PSP
- Phase: 1
- Enrollment: 28 participants (10 AD, 10 PSP, 8 controls)
- Design: Cross-sectional, single-timepoint imaging
- Radioligand: [18F]PI-2620
PSP vs. Controls:
- Significant increase in PI-2620 binding in PSP vs. controls
- Highest binding in globus pallidus, subthalamic nucleus
- Signal intensity correlates with disease severity
- Good differentiation from Parkinson's disease
AD vs. PSP:
- Different regional patterns
- AD: Temporoparietal > frontal
- PSP: Brainstem, basal ganglia > cortex
- Can distinguish 4R vs. 3R/4R tauopathies
Correlation with Clinical Measures:
- PSPRS (PSP Rating Scale) correlates with global tau burden
- Motor symptoms correlate with brainstem binding
- Cognitive measures correlate with cortical binding
- No serious adverse events
- Radiation dose within expected range
- Good tolerability
- No significant off-target effects
- Phase: 2
- Enrollment: 60 participants (40 PSP, 20 controls)
- Design: Longitudinal, multi-timepoint imaging
- Endpoints: SUVr, DVR, BPnd quantification
Reference Region:
- Cerebellar gray matter as reference
- Whole cerebellum as alternative
- Correction for partial volume effects
- Voxel-wise and regional approaches
Quantification Methods:
- Logan graphical analysis for DVR
- Simplified reference tissue model for BPnd
- Voxel-based analysis for spatial patterns
- Region-of-interest based for clinical correlation
- Excellent test-retest reliability (ICC > 0.9)
- Good sensitivity to change over 12 months
- Strong correlation with clinical measures
- Validated against post-mortem data
Scanner Requirements:
- Digital PET or high-resolution PET/CT
- Resolution < 4 mm
- Dynamic or list-mode acquisition capability
Acquisition Protocol:
- Injection: 185-370 MBq [18F]PI-2620
- Frame sequence: 6 × 10s, 6 × 30s, 5 × 120s, 10 × 300s
- Total acquisition: 90 minutes
- CT for attenuation correction
Structural MRI:
- 3D T1-weighted MPRAGE or SPGR
- Resolution: 1 mm isotropic
- Coverage: Whole brain
- Purpose: Anatomical reference, atrophy correction
Advanced MRI (optional):
- T2/FLAIR for white matter lesions
- SWI for iron deposition
- Diffusion imaging for microstructure
- Purpose: Co-registration, anatomical detail
Image Quality Checks:
- Motion artifacts < 2 mm
- Uniform count rates across frames
- Proper attenuation correction
- Absence of reconstruction artifacts
Quantitative Checks:
- SUV recovery coefficients
- Frame alignment quality
- Co-registration with MRI
- SUVr precision < 5%
PI-2620 PET has several diagnostic applications:
Differential Diagnosis:
- PSP vs. Parkinson's disease
- PSP vs. corticobasal degeneration
- PSP vs. AD
- 4R vs. 3R tauopathies
Diagnostic Confidence:
- Positive scan: Supports tauopathy diagnosis
- Negative scan: May indicate alternative diagnosis
- Pattern analysis: Identifies specific tauopathy type
Early Diagnosis:
- Can detect tau pathology before clinical syndrome
- May identify prodromal PSP
- Useful in research settings
Natural History Studies:
- Annual tau accumulation rates
- Regional progression patterns
- Correlation with clinical progression
- Biomarker validation
Treatment Monitoring:
- Target engagement for tau-targeted therapies
- Pharmacodynamic effects
- Dose-response relationships
- Biomarker-guided dose adjustment
Patient Selection:
- Enrich trials with tau-positive patients
- Exclude non-tauopathies
- Stratify by tau burden level
- Identify optimal treatment window
Endpoint Measures:
- SUVr change as pharmacodynamic marker
- Regional binding as target engagement
- Correlation with clinical endpoints
- Surrogate marker potential
PBB3 (APN-1607):
- Parent compound of PI-2620
- Similar binding properties
- PI-2620 has improved manufacturability
- Both show 4R tau specificity
JNJ-311:
- Another 4R tau tracer
- Currently in Phase 1/2 trials
- Similar regional binding pattern
- Comparable sensitivity
GTP-1 (Alzheimer's):
- Primarily for 3R/4R AD tau
- Not optimized for 4R tauopathies
- Different binding characteristics
- Not recommended for PSP
Second-Generation Tracers:
- Higher selectivity
- Better signal-to-noise
- Faster kinetics
- Improved quantification
Dual-Target Tracers:
- Tau + amyloid combination
- Tau + synaptic density
- Tau + neuroinflammation
- Multiple biomarkers
- FDA: No approved indication
- EMA: No approved indication
- Research Use: Available for clinical trials
- Clinical Implementation: Limited availability
Validation Studies:
- Multi-site reproducibility
- Clinical validation against pathology
- Standardization of quantification
- Regulatory qualification
Future Approvals:
- Diagnostic indication likely first
- Companion diagnostic for therapies
- Disease monitoring indication
- Clinical trial enrichment
Improved Quantification:
- Machine learning for automated analysis
- Partial volume correction methods
- Kinetic modeling simplification
- Reference region standardization
Novel Applications:
- Combined PET/MRI protocols
- Theranostic applications
- Radiotherapy planning
- Surgical guidance
Therapeutic Trials:
- Anti-tau therapy monitoring
- Immunotherapy target engagement
- Small molecule efficacy
- Gene therapy tracking
Diagnostic Applications:
- Routine clinical use
- Multi-center standardization
- AI-assisted interpretation
- Integrated diagnostics
PI-2620 PET enables:
- Understanding tau biology — In vivo visualization of tau pathology
- Disease mechanisms — Regional vulnerability patterns
- Biomarker development — Fluid and imaging correlates
- Therapeutic development — Target engagement assessment
- Multi-center imaging consortia
- Clinical trial networks
- Biobank integration
- Precision medicine initiatives
[18F]PI-2620 represents an important advancement in tau imaging for 4R tauopathies like PSP. Its ability to specifically bind to 4R tau aggregates enables:
- Accurate differential diagnosis between tauopathy subtypes
- Disease staging based on regional tau burden
- Clinical trial enrichment with tau-positive patients
- Monitoring of therapeutic target engagement
The ongoing Phase 2 trial (NCT07105384) is validating quantification methodologies that will enable standardized use in clinical practice. As anti-tau therapies enter clinical development, PI-2620 PET will become increasingly important for patient selection and treatment monitoring.
Key advantages over earlier tau tracers include:
- Specificity for 4R tau (critical for PSP)
- Low off-target binding in problematic regions
- Strong correlation with clinical measures
- Good tolerability and safety profile
The development of PI-2620 exemplifies the maturation of molecular imaging in neurodegenerative disease, moving from research tool to clinical utility.
The Phase 1 study demonstrated several key findings:
Tau Binding in PSP
- PI-2620 shows specific binding in PSP-affected brain regions including:
- Globose nucleus
- Subthalamic nucleus
- Red nucleus
- Pontine tegmentum
- Cerebellar dentate nucleus
Signal Characteristics
- Signal intensity correlates with expected tau distribution based on postmortem studies
- Good contrast between affected and unaffected regions
- Suitable for distinguishing PSP from other parkinsonisms
Safety and Tolerability
- No significant adverse events related to tracer administration
- Adequate radiation dosimetry
- Suitable for repeated administration in longitudinal studies
Off-Target Assessment
- Minimal binding in regions problematic for other tracers (e.g., basal ganglia)
- Clean signal in areas of clinical interest
- Enables accurate quantification
The Phase 2 trial is developing:
- Quantification methodologies: Standardized approaches for SUVR calculation
- Reference region validation: Identifying optimal reference tissue for quantification
- Clinical correlation: Linking PET signal to clinical measures (PSPRS, MoCA)
- Longitudinal changes: Understanding natural history of tau accumulation
Standardized acquisition for PI-2620 PET imaging:
Dynamic PET Scanning
- Duration: 0-90 minutes post-injection
- Frames: Multiple frames (e.g., 6 × 30s, 6 × 60s, 10 × 300s)
- Motion correction: List-mode reconstruction with frame-by-frame alignment
MR Imaging
- T1-weighted structural MRI for anatomical reference
- Atrophy correction for partial volume effects
- Region-of-interest definition
Image Processing
- Reconstruction using OSEM or other validated methods
- Spatial normalization to standard space
- Attenuation correction using CT or MR-based approaches
Several quantification methods are employed:
| Method |
Description |
Advantages |
| SUVR |
Standardized uptake value ratio relative to reference region |
Simple, widely used |
| DVR |
Distribution volume ratio using Logan graphical analysis |
Absolute quantification |
| BPnd |
Non-displaceable binding potential |
Quantifies specific binding |
| R1 |
Relative radiotracer delivery |
Assesses blood flow |
Region-of-Interest Analysis
- A priori regions based on PSP neuropathology
- Voxel-wise analysis for exploratory findings
- Region-of-interest templates for standardized reporting
The choice of reference region is critical for accurate quantification:
Cerebellar Gray Matter
- Commonly used reference region
- Assumed to be devoid of specific tau binding in PSP
- Whole cerebellum or specific subregions
- Limitations: May contain some tau pathology in advanced cases
Alternative References
- Pons or brainstem regions
- White matter reference regions
- Need to validate across disease stages
Cross-Validation
- Comparison of multiple reference regions
- Testing in subjects with known pathology
- Consensus guidelines for standardization
| Property |
Value |
| Radioisotope |
Fluorine-18 |
| Half-life |
109.8 minutes |
| Synthesis |
Automated synthesis via nucleophilic fluorination |
| Radiochemical purity |
>95% |
| Specific activity |
High specific activity (>150 GBq/μmol) |
Administration
- Dose: 185-370 MBq (5-10 mCi)
- Injection: Intravenous bolus
- Specific activity: Sufficient for high-quality images
Acquisition Parameters
- PET system: Digital or conventional PET/CT
- Reconstruction: 3D OSEM with scatter correction
- Resolution: Reconstructed resolution ~3-4 mm
Tau PET with PI-2620 has several important clinical applications:
Differential Diagnosis
- Aids in differential diagnosis of parkinsonian syndromes
- Supports confirmation of PSP diagnosis
- Helps distinguish from other causes of dementia
- Can identify tau pathology in clinically uncertain cases
- Supports early diagnosis before significant clinical syndrome develops
Clinical Decision Making
- Confirms tauopathy in diagnostically challenging cases
- Informs prognosis based on burden and distribution
- Guides treatment selection (anti-tau therapies vs. symptomatic treatments)
- Helps identify patients who may benefit from clinical trials
Natural History Studies
- Tau accumulation pattern over disease progression
- Correlation with clinical measures (PSPRS, MoCA, MDS-UPDRS)
- Validation of fluid biomarkers against imaging
- Understanding disease progression patterns
- Neuropathological correlation studies
Therapeutic Development
- Patient stratification for clinical trials
- Pharmacodynamic monitoring of tau-targeting therapies
- Surrogate endpoint for regulatory approval
- Response assessment for disease-modifying treatments
| Biomarker Type |
Correlation with PI-2620 |
Clinical Relevance |
| Neurofilament light chain (NfL) |
Positive correlation |
Disease severity |
| CSF total tau |
Variable |
Disease stage |
| PSP Rating Scale |
Positive correlation |
Clinical severity |
| MoCA |
Negative correlation |
Cognitive impairment |
| Tracer |
Code Name |
3R Affinity |
4R Affinity |
Primary Use |
| [18F]AV-1451 (Flortaucipir) |
Flortaucipir |
High |
Low |
AD (3R/4R) |
| [18F]PI-2620 |
PI-2620 |
Yes |
Yes |
4R tauopathies |
| [18F]PM-PBB3 (APN-1607) |
Atu |
Yes |
Yes |
PSP, CBD |
| [18F]RO948 |
RO948 |
High |
Moderate |
AD |
| [18F]MK-6240 |
MK-6240 |
High |
Low |
AD |
Specific Advantages
- 4R Tau Selectivity: Designed for 4R tauopathies like PSP
- Low Off-Target: Reduced binding to neuromelanin and basal ganglia
- PSP-Typical Regions: Good signal in globose nucleus, subthalamic nucleus
- Quantitative Potential: Suitable for longitudinal monitoring
- Safety Profile: Favorable radiation dosimetry
Limitations
- Less validated in AD compared to flortaucipir
- Availability limited compared to approved tracers
- Quantification methods still being standardized
PI-2620 occupies a unique position in the tau PET landscape:
- For PSP/CBD: First-line choice for 4R tauopathies
- For AD: Complementary to flortaucipir, may detect different tau species
- For Clinical Trials: Essential for patient enrichment and endpoint measurement
The lack of tau imaging has limited:
- Definitive ante-mortem diagnosis
- Understanding of disease mechanisms
- Development of disease-modifying therapies
Tau PET imaging is critical for:
- Diagnosis: Confirming tauopathy in living patients
- Trial Design: Enriching trials with tau-positive patients
- Target Engagement: Demonstrating drug effect on tau
- Natural History: Understanding tau progression
- Differential Diagnosis: Distinguishing tauopathies from other dementias
- Prognostication: Predicting disease progression based on tau burden
- Clinical Trial Endpoints: Providing objective measures for efficacy
Clinical Integration
- Referral patterns for specialist evaluation
- Image interpretation expertise requirements
- Multidisciplinary teams (neurology, radiology, nuclear medicine)
- Quality assurance and standardization
Accessibility
- Need for PET facilities with PI-2620 capability
- Cost considerations for patients and healthcare systems
- Training requirements for image interpretation
- Reimbursement considerations
PI-2620 is in clinical development:
- Phase 1/2 trials completed or ongoing
- Not yet FDA/EMA approved
- Available through clinical trial programs
If Phase 2/3 trials are successful:
- Diagnostic imaging agent for 4R tauopathies
- Companion diagnostic for anti-tau therapies
- Biomarker for patient selection and monitoring
Key considerations:
- Clinical utility for diagnosis and management
- Cost-effectiveness compared to current standard
- Coverage policies for rare diseases like PSP
Multi-Modal Imaging Approaches
- PI-2620 PET combined with FDG-PET for metabolic assessment
- Integration with structural MRI for atrophy patterns
- Amyloid PET (if needed) to rule out concurrent AD
- DAT-SPECT for dopaminergic dysfunction assessment
Data Integration
- Machine learning approaches for multi-modal data fusion
- Composite scores incorporating imaging and clinical data
- Personalized diagnostic algorithms
Anti-Tau Therapy Development
PI-2620 will be critical for emerging anti-tau therapeutic approaches:
Immunotherapy Monitoring
- Anti-tau antibodies binding to extracellular tau
- Tau aggregation inhibitors
- Tau degradation enhancers
Small Molecule Approaches
- Tau acetylation modulators
- Tau phosphorylation inhibitors
- Microtubule stabilizers
Dose-Response Assessment
- Establishing pharmacodynamic relationships
- Determining optimal dosing intervals
- Identifying biomarkers of target engagement
Disease Progression Markers
- Annual rate of tau accumulation in PSP
- Regional patterns of progression
- Correlation with clinical deterioration
- Identification of rapid progressors
Natural History Understanding
- Pre-symptomatic tau detection
- Prodromal PSP identification
- Factors influencing tau spread
Image Quality Standards
- Minimum signal-to-noise ratios
- Spatial resolution requirements
- Motion artifact thresholds
- Reconstruction parameter standards
Standardization Efforts
- Cross-site validation
- Phantom-based quality assurance
- Inter-reader reliability testing
- Harmonization protocols
Automated Analysis Tools
- Region-of-interest automated segmentation
- Voxel-based statistical parametric mapping
- Machine learning classifiers
- Atlas-based quantification
Statistical Approaches
- Group comparison methodologies
- Correlation with clinical endpoints
- Survival analysis for progression
- Multi-center data pooling
Scan Experience
- Total scan time approximately 90 minutes
- Radiation exposure similar to other PET tracers
- Minimal discomfort during procedure
- No special preparation required
Accessibility
- Referral from movement disorder specialists
- Pre-authorization requirements
- Cost considerations for patients
- Travel to specialized centers
Diagnostic Confidence
- Higher certainty in complex cases
- Reduced diagnostic latency
- Improved treatment planning
- Enhanced clinical trial eligibility
Prognostic Information
- Disease staging capabilities
- Progression rate predictions
- Family counseling support
- Care planning assistance
Fluid Biomarker Correlation
- Comparison with CSF tau species
- Blood biomarker validation
- Neurofilament light chain correlations
- Multivariate biomarker panels
Clinical Outcome Correlation
- PSPRS progression correlations
- Cognitive measures relationships
- Functional outcome associations
- Quality of life correlations
Trial Design
- Patient enrichment strategies
- Sample size calculation依据
- Endpoint validation
- Regulatory acceptance
Drug Development
- Target engagement verification
- Dose-selection support
- Registration trial endpoints
- Post-marketing surveillance
¶ Competitive Landscape
| Tracer |
Company |
Status |
Advantages |
| PI-2620 |
Life Molecular Imaging |
Phase 2 |
4R selectivity, low off-target |
| APN-1607 |
Aprinoia |
Phase 2 |
Broader 4R detection |
| CBD-12 |
Avid/Cerebral |
Preclinical |
CBD-specific |
PI-2620's advantages include:
- Optimized for PSP clinical imaging
- Strong safety profile
- Well-characterized kinetics
- Growing clinical evidence base
- Complete Phase 2 trials
- Submit regulatory applications
- Establish imaging protocols
- Train nuclear medicine facilities
- FDA/EMA approval anticipated
- Commercial availability
- Reimbursement negotiations
- Clinical guideline incorporation
- Standard of care for PSP diagnosis
- Integration with therapeutic monitoring
- Expanded indications (CBD, AGD)
- Next-generation tracer development